Skip to main content
. Author manuscript; available in PMC: 2010 Feb 20.
Published in final edited form as: Stat Med. 2008 May 10;27(10):1581–1592. doi: 10.1002/sim.3209

Table III.

The power of the LRT and the power for comparison of estimated target dose 1 (discrete method) with placebo for a 5-dose scenario with σ=1.478.

Model

N Design Const Emax LinL Lin Exp Logist Step 1 Step 2 Step 3
LRT
125 Adaptive 0.07 0.58 0.58 0.56 0.55 0.61 0.57 0.65 0.67
125 Equal 0.05 0.44 0.46 0.45 0.41 0.54 0.42 0.58 0.60
250 Adaptive 0.05 0.85 0.87 0.86 0.88 0.89 0.89 0.90 0.91
250 Equal 0.05 0.71 0.73 0.71 0.71 0.82 0.69 0.86 0.87
Comparison with placebo
250 Adaptive 0.04 0.46 0.44 0.44 0.46 0.47 0.49 0.46 0.47
250 Equal 0.03 0.26 0.23 0.19 0.16 0.26 0.16 0.29 0.37
375 Adaptive 0.04 0.66 0.67 0.66 0.62 0.66 0.65 0.63 0.66
375 Equal 0.03 0.46 0.43 0.37 0.32 0.47 0.35 0.50 0.58
500 Adaptive 0.03 0.81 0.79 0.78 0.70 0.77 0.71 0.75 0.75
500 Equal 0.03 0.66 0.60 0.54 0.44 0.60 0.47 0.61 0.69
750 Adaptive 0.03 0.92 0.91 0.90 0.79 0.86 0.79 0.83 0.84
750 Equal 0.03 0.87 0.83 0.76 0.62 0.77 0.63 0.75 0.82
HHS Vulnerability Disclosure